Semax and Pro-Gly-Pro Modulate Brain Blood Vessel Genes After Stroke
Background
Cerebral ischemia, commonly known as stroke, is a devastating neurological condition caused by reduced blood flow to the brain, leading to neuronal damage and impaired recovery. The VEGF family (Vascular Endothelial Growth Factor) and its receptors are critical for angiogenesis (new blood vessel formation) and neuroprotection, but their precise regulation after stroke is complex and often dysregulated. This study investigates how the peptides Semax and its C-terminal fragment Pro-Gly-Pro influence the expression of VEGF family genes and their receptors following experimental focal ischemia in rats, aiming to uncover their potential therapeutic mechanisms.
Results
In untreated ischemic rats, the study observed a significant increase in the expression of VEGF-A and VEGFR-2 (proteins crucial for blood vessel growth and permeability) compared to healthy controls. Conversely, there was a significant decrease in VEGF-C and VEGFR-3 expression (involved in lymphatic vessel development and neuroprotection) in the ischemic brain. Treatment with Semax or Pro-Gly-Pro effectively normalized the elevated expression of VEGF-A and VEGFR-2 back towards control levels. The most important finding was that both Semax and Pro-Gly-Pro caused a significant increase in the expression of VEGF-C and VEGFR-3 in the ischemic brain, indicating a beneficial shift in angiogenic and neuroprotective pathways that are typically suppressed after stroke. This targeted modulation suggests a unique mechanism of action for these peptides in promoting recovery.
Why It Matters
This research provides compelling evidence that Semax and Pro-Gly-Pro could be promising therapeutic agents for ischemic stroke by beneficially modulating the VEGF system. Their ability to normalize detrimental gene expression changes and, crucially, to increase VEGF-C and VEGFR-3 expression, points towards potential neuroprotective and pro-angiogenic effects vital for brain repair and functional recovery after stroke. These findings lay a strong foundation for further preclinical studies and potentially human clinical trials investigating these peptides as novel treatments for stroke. Future research should focus on dose-response relationships, long-term functional outcomes, and the precise cellular mechanisms involved.